In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
17 authors.
Yuki HoriAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-8340-8989 Hironobu EndoAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0003-3398-597X Kenji TagaiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Yuko KataokaAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Ryoji GotoAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-1693-9915 Shin KuroseAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0001-8355-4946 Yuki MomotaAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Naomi KokuboAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0009-0008-8748-4701 Chie SekiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-3222-7125 Sho MoriguchiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Hitoshi ShimadaAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-7139-7178 Hitoshi ShinotohAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Takahiko TokudaAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Keisuke TakahataAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-0884-4924 Takafumi MinamimotoAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0003-4305-0174 Makoto HiguchiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-3934-5810 Toshiyuki HirabayashiAdvanced Neuroimaging Center, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0009-0009-8870-1074 Funding
Mapping the Human Connectome: Structure, Function, and HeritabilityU54MH091657 · NIMH · WASHINGTON UNIVERSITY · PI UGURBIL, KAMIL, VAN ESSEN, DAVID C · 2010 to 2014
$34.7MNIMH NIH HHS U54 MH091657
6 · The paper itselfAbstract
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with motor and cognitive impairments. Whereas motor symptoms are associated with subcortical tau deposits, the mechanisms underlying the cognitive symptoms remain unclear due to heterogeneous and primarily subcortical distribution of pathological tau deposits. Here, we combined tau-PET (tau positron emission tomography) using a high-contrast probe we developed with a normative connectome in 37 patients with PSP and 48 healthy controls. We found that tau deposition sites functionally connected to a common cortical network that could not be derived from atrophy. This network predominantly overlapped with canonical action-mode and frontoparietal networks, which support adaptive, goal-directed behavior. Whereas the extent of primary tau deposition predicted motor symptoms, the normative connectivity strength from tau deposition sites to the identified cortical network explained the severity of cognitive deficits. These findings suggest a previously unknown mechanism that cognitive, but not motor, deficits in PSP arise from remote effects of tau deposition-independent of atrophy-via convergent connectivity to a common cortical network.
Indexed as
CognitionSupranuclear Palsy, Progressivetau ProteinsAgedConnectomeFemaleHumansMaleMiddle AgedPositron-Emission Tomographytau Proteins
Identifiers
PMID42430462
PMCPMC13353357
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390